On the stock market since 2007, it operates in the world of health and science. Now — the numbers.
This is an established company with proven profits.
No real growth (3% a year).
The gap is $468M. In times of high interest rates, a gap like that can squeeze a company.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, PMC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PMC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.